Over the past few years, the conversation around GLP-1 receptor agonists has been dominated by extremes: dramatic weight loss in clinical trials, before-and-after transformations on social media, and a public discourse that has oscillated between miracle and backlash
Salomon said she is no longer on the medication but is still working hard to keep herself healthy
Our expert team is ready to help you achieve your goals in a safe and supportive environment
That's the scope of the code
RDS, Respiratory distress syndrome
Separately, the Medicare GLP-1 Bridge launches July 1, 2026, giving eligible beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 this operates outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP